Tonix Pharmaceuticals Hld

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Data from Animal Studies of COVID-19 Vaccine Candidate, TNX-1800, Expected in Fourth Quarter 2020

Tonix Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights

Study May Lead to Biomarkers for Tailoring COVID-19 Vaccines and Therapeutics

Tonix Pharmaceuticals Enrolls First Participant in the PRECISION Study, an Observational Study to Facilitate Development of Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics

CHATHAM, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will deliver a Company presentation and host one-on-one meetings during the 2020 BIO Investor Forum Digital, being held virtually October 13-15, 2020. The Company’s presentation will be available on demand to registered participants through the conference website.

Tonix Pharmaceuticals to Participate in BIO Investor Forum Digital

Topline Results of Full Study Expected Fourth Quarter 2020

Tonix Pharmaceuticals Announces Plan to Complete the Phase 3 RELIEF Study of TNX-102 SL for Management of Fibromyalgia with Currently Enrolled Participants Based on Results of Interim Analysis

Facility Addresses the Shortage of Vaccine Production Capacity in the U.S.

Tonix Pharmaceuticals Completes Purchase of Facility to House Advanced Development Center (ADC) for Vaccine Programs

Webinar to be Moderated by Clive Cookson of the Financial Times on September 24, 2020

Tonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?

Results from COV-LOGIC Study Expected in First Half of 2021 Results from COV-LOGIC Study Expected in First Half of 2021

Tonix Pharmaceuticals Enrolls First Patient in COV-LOGIC, an Observational Study to Assess Antibody and T Cell Responses to SARS-CoV-2, the Virus that Causes COVID-19

Interim Analysis Results from Ongoing Phase 3 RELIEF Study Expected in September; Topline Results Expected in Fourth Quarter 2020

Tonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal Phase 3 Study, the RALLY Study, of TNX-102 SL for the Management of Fibromyalgia

NEW YORK, Aug.  27, 2020  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, has been invited to present a Company overview during the following September investor conferences.

Tonix Pharmaceuticals to Participate in Upcoming September Virtual Investor Conferences

Preclinical data for TNX-1800, a Vaccine Candidate to Protect Against COVID-19, Expected in Fourth Quarter 2020

Tonix Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights

NEW YORK, Aug.  06, 2020  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the initiation of a Phase 2 proof-of-concept study using TNX-102 SL for treatment of alcohol use disorder (AUD). The program in AUD is expected to qualify for the 505(b)(2) pathyway for FDA approval.

Tonix Pharmaceuticals Announces Clearance of IND for TNX-102 SL for Treatment of Alcohol Use Disorder

Ideanomics Inc

Electrameccanica

XpresSpa Group

Zomedica

Penny stocks will always be risky. That said, with the huge disconnect we're seeing in the markets, now may be a time to gamble.

The Top 8 Penny Stocks to Buy for August Uncertainty

CleanSpark

Their share prices are predicted to bounce back strongly

Analysts Recommend Buying These 2 Falling Knives

NEW YORK, July  21, 2020  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it is rescheduling the date of the Company’s Special Meeting of Stockholders (the “Special Meeting”) previously scheduled for Friday, June 26, 2020, to Friday, August 28, 2020, at 11:00 a.m., Eastern Time. In connection with the change of the Special Meeting date, the record date for determining stockholders entitled to attend and vote at the Special Meeting has been changed to the close of business on July 15, 2020. 

Tonix Pharmaceuticals Holding Corp. Announces Rescheduling of Special Meeting of Stockholders

ACADIA Pharma

CytoSorbents

Genworth Financial

Hibbett Sports

Limelight Networks

New Age Beverages

Qiwi

The S&P 500 closing up 0.8% at 2,251.84 and with the NASDAQ closing up 2.5% at 10,767.09, many investors are wondering how stocks keep rising despite the major recession in the time of a COVID-19 pandemic.

9 Stocks With Massive Moves in Monday’s After-Hours Session

Dissecting the Immune Response to SARS-CoV-2 in Healthy Recovered or Asymptomatic Volunteers May Lead to Biomarkers for Tailoring COVID-19 Vaccines and Therapeutics

Tonix Pharmaceuticals Announces Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics

NEW YORK, July  15, 2020  (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced registered direct offering, with gross proceeds of approximately $10.5 million before deducting fees and other estimated offering expenses.

Tonix Pharmaceuticals Holding Corp. Closes $10.5 Million Common Stock Registered Direct Offering

NEW YORK, July  13, 2020  (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 20,940,000 shares of common stock, par value $0.001 per share at an offering price of $0.50 per share, pursuant to a registered direct offering. The gross proceeds of the offering will be approximately $10.5 million before deducting fees and other estimated offering expenses. The closing of the registered direct offering is expected to take place on or about July 15, 2020, subject to the satisfaction of customary closing conditions. 

Tonix Pharmaceuticals Holding Corp. Prices $10,500,000 Common Stock Offering

Research to Develop Live Replicating Vaccine (TNX-2300) to Protect Against COVID-19 Based on Bovine Parainfluenza Virus

Tonix Pharmaceuticals Enters into Research and Exclusive License Option Agreement with Kansas State University to Develop Vaccine Against COVID-19

Target Enrollment Completed Ahead of Schedule

Tonix Pharmaceuticals Completes Enrollment in Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia

Tonix's Advanced Development Center Will House Laboratories Dedicated to Process and Analytical Development

Tonix Pharmaceuticals Plans Massachusetts R&D Facility to Accelerate Clinical Development of Vaccines and Protein-Based Therapeutics

Topline Results Expected Fourth Quarter 2020 Due to Faster than Previously Projected Enrollment

Tonix Pharmaceuticals Announces Enrollment of Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia is Ahead of Schedule

TNX-1700 (Stabilized Recombinant Trefoil Factor 2) (rTFF2-CTP) Enhances Anti-tumor Activity of PD-1 blockade in Mouse Models of Colorectal Cancer

Tonix Pharmaceuticals Announces Results from Preclinical Study of TNX-1700 Presented in a Poster at AACR Virtual Annual Meeting 2020

Plan to Produce Blueprint of How the Human Immune System Responds to Infection Caused by SAR-CoV-2, the Virus that Causes COVID-19

Tonix Pharmaceuticals and Southern Research Announce Expansion of COVID-19 Vaccine Collaboration

NEW YORK, June  17, 2020  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that preclinical results of TNX-1700 (rTFF2) will be presented in a poster at the American Association of Cancer Research (AACR) Virtual Annual Meeting II. The meeting is being held June 22-24, 2020.

Tonix Pharmaceuticals Announces that Results from Preclinical Studies of TNX-1700 Will be Presented in a Poster at the AACR Virtual Annual Meeting 2020

News for Tonix Pharmaceuticals Hld Stock (TNXP)